Literature DB >> 10616015

Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit.

C Bryan1, C Knight, C M Black, A J Silman.   

Abstract

OBJECTIVE: To identify combinations of easily acquired clinical variables, at first presentation with scleroderma, that would predict subsequent mortality.
METHODS: In this prospective study of all new patients at one major scleroderma center, 280 patients with definite scleroderma (according to the American College of Rheumatology criteria) whose disease onset occurred from 1982 to 1991 and who were followed up to the end of 1996 were identified. Standardized data collection was performed at entry to obtain data on major clinical and laboratory variables. Vital status was determined by linkage to the National Death Index.
RESULTS: At 5 years, 55 (26%) of 215 women and 21 (32%) of 65 men had died. Univariate analysis showed that older age, diffuse skin disease, higher skin score, low carbon monoxide diffusing capacity, abnormal electrocardiogram findings, proteinuria, hematuria, low hemoglobin level, elevated erythrocyte sedimentation rate (ESR), and presence of antitopoisomerase antibody were all associated with increased mortality. A logistic regression model, validated by Monte Carlo simulation, identified 3 factors, proteinuria, elevated ESR, and low carbon monoxide diffusing capacity, that in combination, had an accuracy of >80% in predicting mortality. The absence of these 3 factors was associated with 93% survival.
CONCLUSION: A simple model has been developed that appears to accurately predict mortality over 5 years in a cohort of patients newly presenting with scleroderma.

Entities:  

Mesh:

Year:  1999        PMID: 10616015     DOI: 10.1002/1529-0131(199912)42:12<2660::AID-ANR23>3.0.CO;2-N

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  36 in total

Review 1.  Stem cell transplantation for autoimmune diseases.

Authors:  J Moore; P Brooks
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Stem cell transplantation: limits and hopes.

Authors:  K P Machold; J S Smolen
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

3.  Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.

Authors:  M Binks; J R Passweg; D Furst; P McSweeney; K Sullivan; C Besenthal; J Finke; H H Peter; J van Laar; F C Breedveld; W E Fibbe; D Farge; E Gluckman; F Locatelli; A Martini; F van den Hoogen; L van de Putte; A V Schattenberg; R Arnold; P A Bacon; P Emery; I Espigado; B Hertenstein; F Hiepe; A Kashyap; I Kötter; A Marmont; A Martinez; M J Pascual; A Gratwohl; H G Prentice; C Black; A Tyndall
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

4.  High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.

Authors:  Peter A McSweeney; Richard A Nash; Keith M Sullivan; Jan Storek; Leslie J Crofford; Roger Dansey; Maureen D Mayes; Kevin T McDonagh; J Lee Nelson; Theodore A Gooley; Leona A Holmberg; C S Chen; Mark H Wener; Katherine Ryan; Julie Sunderhaus; Ken Russell; John Rambharose; Rainer Storb; Daniel E Furst
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

5.  Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.

Authors:  D Farge; J Passweg; J M van Laar; Z Marjanovic; C Besenthal; J Finke; H H Peter; F C Breedveld; W E Fibbe; C Black; C Denton; I Koetter; F Locatelli; A Martini; A V N Schattenberg; F van den Hoogen; L van de Putte; F Lanza; R Arnold; P A Bacon; S Bingham; F Ciceri; B Didier; J L Diez-Martin; P Emery; W Feremans; B Hertenstein; F Hiepe; R Luosujärvi; A Leon Lara; A Marmont; A M Martinez; H Pascual Cascon; C Bocelli-Tyndall; E Gluckman; A Gratwohl; A Tyndall
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

6.  [Systemic sclerosis].

Authors:  S Kleinert; H P Tony; C Kneitz
Journal:  Internist (Berl)       Date:  2006-10       Impact factor: 0.743

7.  Changes in causes of death in systemic sclerosis, 1972-2002.

Authors:  Virginia D Steen; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

8.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.

Authors:  Richard A Nash; Peter A McSweeney; Leslie J Crofford; Muneer Abidi; Chien-Shing Chen; J David Godwin; Theodore A Gooley; Leona Holmberg; Gretchen Henstorf; C Fred LeMaistre; Maureen D Mayes; Kevin T McDonagh; Bernadette McLaughlin; Jerry A Molitor; J Lee Nelson; Howard Shulman; Rainer Storb; Federico Viganego; Mark H Wener; James R Seibold; Keith M Sullivan; Daniel E Furst
Journal:  Blood       Date:  2007-04-23       Impact factor: 22.113

9.  Autoantibody profile in systemic sclerosis as a marker for esophageal and other organ involvement in Turkish populations.

Authors:  Nurten Savas; Ulku Dagli; Esin Ertugrul; Sedef Kuran; Burhan Sahin
Journal:  Dig Dis Sci       Date:  2007-03-28       Impact factor: 3.199

10.  Oxidative stress in Mexicans with diffuse cutaneous systemic sclerosis.

Authors:  M P Cruz-Domínguez; D H Montes-Cortes; I M Olivares-Corichi; O Vera-Lastra; G Medina; L J Jara
Journal:  Rheumatol Int       Date:  2013-03-02       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.